JP2022549335A5 - - Google Patents

Info

Publication number
JP2022549335A5
JP2022549335A5 JP2022519061A JP2022519061A JP2022549335A5 JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5 JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5
Authority
JP
Japan
Prior art keywords
psychosis
symptoms
schizophrenia
disorder
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022519061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052923 external-priority patent/WO2021062307A1/en
Publication of JP2022549335A publication Critical patent/JP2022549335A/ja
Publication of JP2022549335A5 publication Critical patent/JP2022549335A5/ja
Priority to JP2025182550A priority Critical patent/JP7821366B1/ja
Withdrawn legal-status Critical Current

Links

JP2022519061A 2019-09-25 2020-09-25 新規方法 Withdrawn JP2022549335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182550A JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906042P 2019-09-25 2019-09-25
US62/906,042 2019-09-25
PCT/US2020/052923 WO2021062307A1 (en) 2019-09-25 2020-09-25 Novel methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182550A Division JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Publications (2)

Publication Number Publication Date
JP2022549335A JP2022549335A (ja) 2022-11-24
JP2022549335A5 true JP2022549335A5 (enExample) 2023-10-02

Family

ID=75166462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519061A Withdrawn JP2022549335A (ja) 2019-09-25 2020-09-25 新規方法
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Country Status (4)

Country Link
US (2) US12478623B2 (enExample)
EP (1) EP4034119A4 (enExample)
JP (2) JP2022549335A (enExample)
WO (1) WO2021062307A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148303C (en) * 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
EP4273550A3 (en) 2018-05-17 2024-04-03 Northeastern University Lipid-free anchoring of thermophilic bacteriophage g20c portal adapter into solid-state nanopores
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
US20230312573A1 (en) * 2020-09-04 2023-10-05 Intra-Cellular Therapies, Inc. Novel salts, crystals, and co-crystals
WO2025111568A1 (en) * 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AR024378A1 (es) 1999-06-15 2002-10-02 Du Pont Pharm Co Gamma-carbolinas fusionadas heterociclicas sustituidas
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
KR20030070073A (ko) 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050058703A1 (en) 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
JP2009502961A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP2262502A4 (en) 2008-02-05 2011-12-28 Clera Inc Compositions and methods for alleviating depression or improving cognition
SI2262505T1 (sl) 2008-03-12 2015-03-31 Intra-Cellular Therapies, Inc. Substituirana heterociklirano zliti gama-karbolinska trdna snov
WO2009145900A1 (en) 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
RU2591194C2 (ru) 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
KR20150056608A (ko) 2012-09-14 2015-05-26 아비에 도이치란트 게엠베하 운트 콤파니 카게 트리사이클릭 퀴놀린 및 퀴녹살린 유도체
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
EP3043777B1 (en) 2013-09-10 2020-04-22 Fresh Cut Development, LLC Sublingual buprenorphine spray
CA3148303C (en) 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US11123311B2 (en) 2016-01-05 2021-09-21 The Regents Of The University Of California Methods of treating mental disorders
PT3407888T (pt) * 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
JP7223742B2 (ja) * 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
CN109867674A (zh) 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
DK3768271T3 (da) 2018-03-23 2026-03-02 Intra Cellular Therapies Inc Organiske forbindelser
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) * 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
EP4744678A2 (en) 2019-12-19 2026-05-20 Intra Cellular Therapies Inc LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA
IL316924A (en) 2022-05-18 2025-01-01 Intra Cellular Therapies Inc Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Similar Documents

Publication Publication Date Title
AU2021202433B2 (en) Neuroactive steroids, compositions, and uses thereof
KR102228598B1 (ko) 최면 진정제의 투여 방법
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
DE4218572A1 (de) Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
JP2008545793A5 (enExample)
US9782404B2 (en) Methods of treating disease-induced ataxia and non-ataxic imbalance
JP2021505575A5 (enExample)
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
EA021962B1 (ru) Способ лечения шизофрении
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
JP2021530543A5 (enExample)
ES2963362T3 (es) Métodos de uso de derivados de amidas cíclicas para tratar la esquizofrenia y sus síntomas
RU2019132951A (ru) Применение обратного агониста h3r для лечения расстройства сна при сменной работе
Varghese et al. Lamotrigine‐induced toxic epidermal necrolysis in three patients treated for bipolar disorder
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ［１，２−ａ］イミダゾールジオン
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
ES2969657T3 (es) Tratamiento de trastorno de síndrome postraumático
JPH02212426A (ja) 医薬組成物
HK40009151A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40009154A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40009154B (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2025019604A2 (en) Proteolysis targeting chimeras for treating neurodegeneration
CN102552266A (zh) 双苄基异喹啉类化合物或其在药学上可接受的盐在制备改善睡眠的药品或保健品中的应用